Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aldeyra Therapeutics, Inc.ALDX · Entity 6839 | Director | June 09, 2026 | June 11, 2026 |
| GENOCEA BIOSCIENCES, INC.GNCA · Entity 12635 | Director · President and CEO | June 02, 2022 | June 03, 2022 |
| X4 Pharmaceuticals, IncASNS · Entity 5638 | Director | June 05, 2018 | June 07, 2018 |
| iBio, Inc.IBIO · Entity 6906 | Director | November 20, 2025 | November 24, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aldeyra Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2036-06-08 | Direct | 70,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 70,000 · Balance 70,000 F1: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2036-06-08 | Direct | 2,323 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 2,323 · Balance 2,323 F2: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
F2: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date.
GENOCEA BIOSCIENCES, INC.
Report date June 02, 2022 · Filed June 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 304,377 |
Reported balance
After 2022-06-02 transaction · row 1
1 source rowRow 1 · 2022-06-02 · Sale · Disposed 4,023 · Balance 304,377 F1: Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person.
X4 Pharmaceuticals, Inc
Report date June 05, 2018 · Filed June 07, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.99 · Expires 2028-06-04 | Direct | 10,000 |
Reported balance
After 2018-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-05 · Grant · Acquired 10,000 · Balance 10,000 F1: The option becomes exercisable as to 1/12th of the shares underlying the award on the one-month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option becomes exercisable as to 1/12th of the shares underlying the award on the one-month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date.
iBio, Inc.
Report date November 20, 2025 · Filed November 24, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2035-11-19 | Direct | 13,500 |
Reported balance
After 2025-11-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-20 · Grant · Acquired 13,500 · Balance 13,500 F1: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 11, 2026 20:23 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 2,323 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001193125-26-267611 · ownership.xml · derivative · entry 2 Clark William D · CIK 0001355415 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,323 Underlying: Common Stock · 2,323 shares Expires 2036-06-08 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:23 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001193125-26-267611 · ownership.xml · derivative · entry 1 Clark William D · CIK 0001355415 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-06-08 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:09 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001104659-25-115411 · tm2532045-5_4seq1.xml · derivative · entry 1 Clark William D · CIK 0001355415 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 13,500 shares Expires 2035-11-19 F1 · security: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. F1 · shares: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. Read SEC document |
| April 17, 2025 Filed Apr 18, 2025 20:41 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 76,760 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0000950170-25-055900 · ownership.xml · derivative · entry 1 Clark William D · CIK 0001355415 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,760 Underlying: Common Stock · 76,760 shares Expires 2035-04-16 F1 · derivative.exercise_date: The stock option is exercisable in equal annual installments over three years of continuous service to the Issuer after April 17, 2025. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 21:31 UTC | iBio, Inc. IBIO · Entity 6906 | PurchaseCommon Stock | 1,838 | $2.72 | $4,999.36 |
DisclosureSEC source: 0001104659-25-003060 · tm253156-3_4seq1.xml · nonDerivative · entry 1 Clark William D · CIK 0001355415 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,838 F1 · kind: Shares purchased by Reporting Person pursuant to a Securities Purchase Agreement with iBio, Inc., dated January 10, 2025. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 21:32 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 18,900 | $0.00 Strike: $2.45 | $0.00 |
DisclosureSEC source: 0001104659-24-122590 · tm2429436-3_4seq1.xml · derivative · entry 1 Clark William D · CIK 0001355415 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,900 Underlying: Common Stock · 18,900 shares Expires 2034-11-20 F1 · security: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. F1 · shares: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 16:11 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | SaleCommon Stock | 4,023 | $0.06 | $241.38 |
DisclosureSEC source: 0001457612-22-000073 · wf-form4_165428706230667.xml · nonDerivative · entry 1 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,377 F1 · shares: Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 16:31 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | SaleCommon Stock | 117,244 | $0.06 | $7,233.95 |
DisclosureSEC source: 0001457612-22-000069 · wf-form4_165420185009155.xml · nonDerivative · entry 1 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,400 F1 · price: 1. Represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $0.061 to $0.0628, inclusive. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 08:15 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | SaleCommon Stock | 3,924 | $1.25 | $4,905.00 |
DisclosureSEC source: 0001457612-22-000043 · wf-form4_164916091313327.xml · nonDerivative · entry 1 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,487 F1 · shares: Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 16, 2022 Filed Mar 17, 2022 16:06 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | SaleCommon Stock | 11,435 | $1.10 | $12,578.50 |
DisclosureSEC source: 0001457612-22-000026 · wf-form4_164754760130122.xml · nonDerivative · entry 2 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 373,411 F2 · shares: Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 16:06 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001457612-22-000026 · wf-form4_164754760130122.xml · derivative · entry 3 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2032-03-15 F3 · derivative.exercise_date: The options are scheduled to vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date. Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 16:06 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001457612-22-000026 · wf-form4_164754760130122.xml · nonDerivative · entry 1 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,846 F1 · shares: Restricted stock units that represent the contingent right to receive, at settlement, one share of common stock. The restricted stock units are scheduled to vest 25% on each of the first four anniversaries of the grant date. Read SEC document |
| December 09, 2021 Filed Dec 14, 2021 00:12 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 109,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001104659-21-149239 · tm2135158-8_4seq1.xml · derivative · entry 1 Clark William D · CIK 0001355415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,000 Underlying: Common Stock · 109,000 shares Expires 2031-12-08 F1 · security: These options vest pro rata on a monthly basis over 12 months. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 12 months. Read SEC document |
| August 23, 2021 Filed Aug 26, 2021 00:31 UTC | iBio, Inc. IBIO · Entity 6906 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001104659-21-109466 · tm2125787d5_4seq1.xml · derivative · entry 1 Clark William D · CIK 0001355415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-08-22 F1 · security: These options vest pro rata on a monthly basis over 36 months. F1 · derivative.exercise_date: These options vest pro rata on a monthly basis over 36 months. Read SEC document |
| June 01, 2021 Filed Mar 16, 2022 17:28 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | SaleCommon Stock | 2,080 | $2.23 | $4,638.40 |
DisclosureSEC source: 0001457612-22-000016 · wf-form5_164746606175514.xml · nonDerivative · entry 2 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,003 F1 · shares: Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| April 02, 2021 Filed Mar 16, 2022 17:28 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | SaleCommon Stock | 3,794 | $2.71 | $10,281.74 |
DisclosureSEC source: 0001457612-22-000016 · wf-form5_164746606175514.xml · nonDerivative · entry 1 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,083 F1 · shares: Sale of shares by the Reporting Person to cover personal income tax withholding obligations in connection with the vesting and settlement of restricted stock units. Sell-to-cover is required by the Issuer, and this sale does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 13:56 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantRestricted Stock Unit · Derivative | 600,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001457612-21-000040 · wf-form4_161600378970314.xml · derivative · entry 3 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Common Stock · 600,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F4 · derivative.exercise_date: Vesting of these restricted stock units depends on the average closing price of a share of Genocea Biosciences, Inc.'s common stock over the sixty trading days immediately preceding December 31, 2023. The "target" number of restricted stock units is reported. Between 75% and 150% of the target number of units may vest on December 31, 2023, with the vesting percentage determined based on actual performance. F4 · derivative.expiration_date: Vesting of these restricted stock units depends on the average closing price of a share of Genocea Biosciences, Inc.'s common stock over the sixty trading days immediately preceding December 31, 2023. The "target" number of restricted stock units is reported. Between 75% and 150% of the target number of units may vest on December 31, 2023, with the vesting percentage determined based on actual performance. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 13:56 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 450,000 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001457612-21-000040 · wf-form4_161600378970314.xml · derivative · entry 2 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2031-03-15 F2 · derivative.exercise_date: The option will vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 13:56 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001457612-21-000040 · wf-form4_161600378970314.xml · nonDerivative · entry 1 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 F1 · shares: Restricted stock units that represent the contingent right to receive, at settlement, one share of common stock. The restricted stock units are scheduled to vest 25% on each of the first four anniversaries of the grant date. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 11:25 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,500 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001457612-21-000016 · wf-form4_161366552090427.xml · derivative · entry 4 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,000 Underlying: Common Stock · 16,500 shares Expires 2030-04-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option was granted on 4/2/2020 and vests in 48 equal monthly installments beginning on the first monthly anniversary of the grant date. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 11:25 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | Exercise / conversionStock Option (Right to Buy) · Derivative | 19,998 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001457612-21-000016 · wf-form4_161366552090427.xml · derivative · entry 3 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,690 Underlying: Common Stock · 19,998 shares Expires 2030-06-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option was granted on 6/1/2020 and vests in 48 equal monthly installments beginning on the first monthly anniversary of the grant date. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 11:25 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | Exercise / conversionCommon Stock | 19,998 | $2.72 | $54,394.56 |
DisclosureSEC source: 0001457612-21-000016 · wf-form4_161366552090427.xml · nonDerivative · entry 2 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 11:25 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | Exercise / conversionCommon Stock | 16,500 | $1.66 | $27,390.00 |
DisclosureSEC source: 0001457612-21-000016 · wf-form4_161366552090427.xml · nonDerivative · entry 1 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2020 Filed Nov 10, 2020 14:45 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | PurchaseCommon Stock | 4,760 | $2.06 | $9,805.60 |
DisclosureSEC source: 0001457612-20-000176 · wf-form4_160503752402158.xml · nonDerivative · entry 1 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,760 Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 16:18 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 106,688 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001457612-20-000078 · wf-form4_159112907688979.xml · derivative · entry 2 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,688 Underlying: Common Stock · 106,688 shares Expires 2030-06-01 F2 · derivative.exercise_date: The option will vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 16:18 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantCommon Stock | 27,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001457612-20-000078 · wf-form4_159112907688979.xml · nonDerivative · entry 1 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,344 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Amended and Restated 2014 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest one-fourth (1/4) on each of the first four (4) anniversaries on the date of grant. Read SEC document |
| April 02, 2020 Filed Apr 6, 2020 16:24 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 187,500 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001457612-20-000035 · wf-form4_158620462528432.xml · derivative · entry 2 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2030-04-02 F2 · derivative.exercise_date: The option will vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date. Read SEC document |
| April 02, 2020 Filed Apr 6, 2020 16:24 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantCommon Stock | 50,783 | $0.00 | $0.00 |
DisclosureSEC source: 0001457612-20-000035 · wf-form4_158620462528432.xml · nonDerivative · entry 1 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,783 F1 · shares: Represents restricted stock units granted to the Reporting Person under the Amended and Restated 2014 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share ofthe Issuer's common stock. The restricted stock units shall vest on the one-year anniversary of March 6, 2020, subject to the Reporting Person's continued service with the Issuer through the vesting date. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 13:34 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001457612-19-000038 · wf-form4_155293042694222.xml · derivative · entry 2 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 735,000 Underlying: Common Stock · 15,000 shares Expires 2029-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: (1) The option was granted on 02/07/2019 and vests in 48 equal monthly installments beginning on the first monthly anniversary of the grant date. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 13:34 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | Exercise / conversionCommon Stock | 15,000 | $0.54 | $8,100.00 |
DisclosureSEC source: 0001457612-19-000038 · wf-form4_155293042694222.xml · nonDerivative · entry 1 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 21:00 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 750,000 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001457612-19-000017 · wf-form4_154993682327409.xml · derivative · entry 1 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2029-02-07 F1 · derivative.exercise_date: The Stock Option will vest as to 1/4th of the shares subject to the option on the first anniversary of the Grant Date and thereafter as to 1/36th of the shares on each subsequent monthly anniversary of February 7, 2020 (rounded down to the nearest whole share, except for the final vesting period, with respect to which all remaining shares will vest). Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 20:06 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 468,000 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001457612-18-000066 · wf-form4_152997156749848.xml · derivative · entry 1 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 864,000 Underlying: Common Stock · 468,000 shares Expires 2028-02-07 F1 · derivative.exercise_date: The Company's Board of Directors approved these options on February 8, 2018, subject to stockholder approval of an amendment to the Company's 2014 Equity Incentive Plan (the "Plan"); such stockholder approval for the amendment of the Plan was obtained on June 21, 2018. The options commence vesting on February 8, 2018 (the "Vesting Commencement Date") and will vest as to 1/4th of the shares subject to the option on the first anniversary of the Vesting Commencement Date and thereafter as to 1/36th of the shares on each subsequent monthly anniversary of the Vesting Commencement Date (rounded down to the nearest whole share, except for the final vesting period, with respect to which all remaining shares will vest), subject to each individual's continued employment with the Company on each such vesting date. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:17 UTC | X4 Pharmaceuticals, Inc ASNS · Entity 5638 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.99 | $0.00 |
DisclosureSEC source: 0001209191-18-036334 · doc4.xml · derivative · entry 1 Clark William D · CIK 0001355415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-04 F1 · derivative.exercise_date: The option becomes exercisable as to 1/12th of the shares underlying the award on the one-month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 20:26 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 396,000 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001457612-18-000015 · wf-form4_151848519091641.xml · derivative · entry 1 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,000 Underlying: Common Stock · 396,000 shares Expires 2028-02-07 F1 · derivative.exercise_date: The options granted will vest annually in 48 equal monthly installments beginning on the first monthly anniversary of the grant date. The Company's Board of Directors also approved on February 8, 2018 that, subject to stockholder approval, William D. Clark will receive 468,000 additional options with the same grant date, at the same exercise price and pursuant to the same vesting schedule. Read SEC document |
| January 17, 2018 Filed Jan 19, 2018 15:21 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | PurchaseCommon Stock | 25,000 | $0.80 | $20,000.00 |
DisclosureSEC source: 0001457612-18-000001 · wf-form4_151639329232626.xml · nonDerivative · entry 1 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,931 Read SEC document |
| November 15, 2017 Filed Dec 1, 2017 22:26 UTC | X4 Pharmaceuticals, Inc ASNS · Entity 5638 | GrantStock Option (right to buy) · Derivative | 7,324 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0000899243-17-027832 · doc4.xml · derivative · entry 1 Clark William D · CIK 0001355415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,324 Underlying: Common Stock · 7,324 shares Expires 2027-11-14 F1 · security: Consists of an automatic stock option grant that was made on November 15, 2017, the date of the effectiveness of the registration statement for the issuer's initial public offering, under the issuer's director compensation program. F2 · derivative.exercise_date: The option becomes exercisable as to 33.3333% of the shares underlying the award on the first anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date. Read SEC document |
| November 15, 2017 Filed Mar 5, 2018 21:49 UTC Amendment | X4 Pharmaceuticals, Inc ASNS · Entity 5638 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001209191-18-016529 · doc4a.xml · derivative · entry 1 Clark William D · CIK 0001355415 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-11-14 F1 · shares: Consists of an automatic stock option grant that was made pursuant to the issuer's director compensation policy on November 15, 2017, the date of effectiveness of the registration statement for the issuer's initial public offering. Under the terms of the policy, the Reporting Person received an option to purchase 25,000 shares. Due to a clerical error, the original Form 4 filed on December 1, 2017 erroneously reported an option grant of 7,324 shares. This Amendment to Form 4 is filed solely to correct the share number. F2 · derivative.exercise_date: The option becomes exercisable as to 33.3333% of the shares underlying the award on the first anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the Reporting Person's continued service as a director through each applicable vesting date. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 16:19 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | GrantStock Option (Right to Buy) · Derivative | 288,000 | $0.00 Strike: $4.67 | $0.00 |
DisclosureSEC source: 0001355415-17-000002 · wf-form4_148840317772190.xml · derivative · entry 1 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,000 Underlying: Common Stock · 288,000 shares Expires 2027-02-28 F1 · derivative.exercise_date: 1. The option will vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date. Read SEC document |
| November 07, 2016 Filed Nov 9, 2016 17:29 UTC | GENOCEA BIOSCIENCES, INC. GNCA · Entity 12635 | PurchaseCommon Stock | 2,800 | $3.49 | $9,772.00 |
DisclosureSEC source: 0001355415-16-000004 · wf-form4_147873057321480.xml · nonDerivative · entry 1 Clark William D · CIK 0001355415 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,205 F1 · balance_after: Amount adjusted to reflect shares acquired under the registrant's Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.